FDA pharmacologic class
Adenosine Triphosphate-Citrate Lyase Inhibitor
1 medicine is in FDA's class of adenosine triphosphate-citrate lyase inhibitors: bempedoic acid (Nexletol); 1 combination product also contains one. 0 of the 2 are listed from generic labelers (FDA NDC Directory, October 8, 2026). The lowest pharmacy cost is nexlizet 180-10 mg tablet at $13.80 per tablet (NADAC).
Which medicines are adenosine triphosphate-citrate lyase inhibitor?
| Medicine | Brand names | Generic labelers (all forms) | Pharmacy cost | Boxed warning | Shortage | Recalls since 2012 |
|---|---|---|---|---|---|---|
| Bempedoic acid | Nexletol | none listed | $13.81 per tablet 180 mg tablet | No | No current entry | 0 |
| Bempedoic acid and ezetimibe | Nexlizet | none listed | $13.80 per tablet 180-10 mg tablet | No | No current entry | 2 |
Source: FDA Established Pharmacologic Class (NDC Directory, openFDA); CMS NADAC of October 7, 2026; FDA shortages and recalls (FDA files October 8, 2026)
What do pharmacies pay?
Each medicine's most widely listed form, per unit, in the NADAC survey: what pharmacies paid, not what a patient pays; strengths differ, so compare like with like.
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price